NUS — NU Skin Enterprises Balance Sheet
0.000.00%
- $529.13m
- $512.66m
- $1.73bn
- 96
- 94
- 85
- 100
Annual balance sheet for NU Skin Enterprises, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
| 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K | 
| Standards: | USG | USG | USG | USG | USG | 
| Status: | Final | Final | Final | Final | Final | 
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 457 | 356 | 280 | 270 | 202 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 63.4 | 41.3 | 47.4 | 72.9 | 50.8 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 903 | 873 | 760 | 702 | 539 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 623 | 575 | 558 | 534 | 462 | 
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,957 | 1,906 | 1,821 | 1,806 | 1,469 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 543 | 530 | 359 | 329 | 297 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1,063 | 994 | 924 | 984 | 817 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 894 | 913 | 897 | 822 | 651 | 
| Total Liabilities & Shareholders' Equity | 1,957 | 1,906 | 1,821 | 1,806 | 1,469 | 
| Total Common Shares Outstanding |